PL1810676T3 - Formulacje lewetiracetamu i sposoby ich wytwarzania - Google Patents

Formulacje lewetiracetamu i sposoby ich wytwarzania

Info

Publication number
PL1810676T3
PL1810676T3 PL06251210T PL06251210T PL1810676T3 PL 1810676 T3 PL1810676 T3 PL 1810676T3 PL 06251210 T PL06251210 T PL 06251210T PL 06251210 T PL06251210 T PL 06251210T PL 1810676 T3 PL1810676 T3 PL 1810676T3
Authority
PL
Poland
Prior art keywords
methods
manufacture
levetiracetam
compositions
formulations
Prior art date
Application number
PL06251210T
Other languages
English (en)
Inventor
Julia Hrakovsky
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1810676(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of PL1810676T3 publication Critical patent/PL1810676T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PL06251210T 2006-01-24 2006-03-07 Formulacje lewetiracetamu i sposoby ich wytwarzania PL1810676T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76210306P 2006-01-24 2006-01-24
EP06251210A EP1810676B1 (en) 2006-01-24 2006-03-07 Levetiracetam formulations and methods for their manufacture

Publications (1)

Publication Number Publication Date
PL1810676T3 true PL1810676T3 (pl) 2009-04-30

Family

ID=36337638

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06251210T PL1810676T3 (pl) 2006-01-24 2006-03-07 Formulacje lewetiracetamu i sposoby ich wytwarzania

Country Status (13)

Country Link
US (1) US20070172521A1 (pl)
EP (1) EP1810676B1 (pl)
JP (1) JP2009524658A (pl)
CN (1) CN101360493A (pl)
AT (1) ATE413875T1 (pl)
CA (1) CA2637925A1 (pl)
DE (1) DE602006003617D1 (pl)
DK (1) DK1810676T3 (pl)
ES (1) ES2317452T3 (pl)
IL (1) IL193024A0 (pl)
PL (1) PL1810676T3 (pl)
PT (1) PT1810676E (pl)
WO (1) WO2007086891A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2197428B1 (en) 2007-10-16 2012-01-25 Pharmathen S.A. Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
WO2009069089A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Levetiracetam controlled release composition
WO2009135646A2 (en) * 2008-05-05 2009-11-12 Farmaprojects, Sa Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
NZ598744A (en) 2009-09-18 2013-11-29 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
CN101693017B (zh) * 2009-10-28 2012-06-06 北京赛科药业有限责任公司 左乙拉西坦的药物组合物及其制备方法
EP2563340A2 (en) 2010-04-26 2013-03-06 Mahmut Bilgic Water soluble pharmaceutical composition
EP2387993B1 (en) * 2010-05-21 2012-11-07 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of zolmitriptan and process for preparing the same
CN102379857B (zh) * 2011-05-30 2013-10-09 深圳信立泰药业股份有限公司 一种左乙拉西坦缓释药物组合物及其制备方法
CN102764254B (zh) * 2012-05-16 2016-09-07 深圳信立泰药业股份有限公司 一种左乙拉西坦药物组合物及其制备方法
JP6630229B2 (ja) * 2016-05-17 2020-01-15 エルメッド株式会社 レベチラセタム含有医薬組成物及びその製造方法
JP6422464B2 (ja) * 2016-05-19 2018-11-14 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
JP6326114B2 (ja) * 2016-11-01 2018-05-16 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
JP7575217B2 (ja) * 2019-08-09 2024-10-29 日本ジェネリック株式会社 レベチラセタムを含む錠剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514389A (en) * 1981-05-06 1985-04-30 Kyowa Chemical Industry Co. Ltd. Gastric antacid and method for controlling pH of gastric juice
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
AR026610A1 (es) * 1999-12-01 2003-02-19 Ucb Sa Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
US20040116506A1 (en) * 2002-06-20 2004-06-17 Krusz John Claude Use of levetiracetam for treating or preventing acute headaches
CN1205938C (zh) * 2002-10-08 2005-06-15 深圳海王药业有限公司 具有改善哺乳动物微循环作用的产品
CN1802352A (zh) * 2003-02-03 2006-07-12 特瓦制药工业有限公司 制备左乙拉西坦的方法
AU2003217438A1 (en) * 2003-03-18 2004-10-11 Hetero Drugs Limited Novel crystalline forms of levetiracetam
EP1663968A1 (en) * 2003-09-05 2006-06-07 Ranbaxy Laboratories Limited Process for the preparation of pure levetiracetam
AU2006274263B2 (en) * 2005-07-26 2011-01-27 Ucb Pharma, S.A. Pharmaceutical compositions comprising levetiracetam and process for their preparation

Also Published As

Publication number Publication date
EP1810676A1 (en) 2007-07-25
IL193024A0 (en) 2009-02-11
US20070172521A1 (en) 2007-07-26
EP1810676B1 (en) 2008-11-12
JP2009524658A (ja) 2009-07-02
WO2007086891A1 (en) 2007-08-02
ES2317452T3 (es) 2009-04-16
CN101360493A (zh) 2009-02-04
DE602006003617D1 (de) 2008-12-24
PT1810676E (pt) 2009-01-02
ATE413875T1 (de) 2008-11-15
DK1810676T3 (da) 2009-02-09
CA2637925A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
IL193024A0 (en) Levetiracetam formulations and methods for their manufacture
EP2535058A3 (en) Stabilization of vaccines by lyophilization
NO20092611L (no) Krystallinsk faststoff Rasagilin base
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
PH12014502880A1 (en) Lyophilized therapeutic peptibody formulations
IL190915A0 (en) Dry formulations of aripiprazole
TW200800967A (en) Benzimidazole thiophene compounds
WO2007106746A3 (en) Formulations for ecallantide
GEP20094784B (en) Sustained release pharmaceutical formulations
IL186127A (en) Subcutaneous preparations for the treatment of depression and methods for their preparation
TW200738659A (en) Novel compounds
TW200730518A (en) Crystalline forms of docetaxel and processes for their preparation
IL190774A0 (en) Pharmaceutical compositions containing a jorumycin-renieramycin-or saframycin-related compounds for treating proliferative diseases
HUP0401523A3 (en) Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
TW200738649A (en) Calcilytic compounds
EP1991248A4 (en) ANTIDEPRESSANT PRODRUGS
TNSN07241A1 (en) Substituted pyrroles, compositions containing same, method for making same and use thereof
WO2006091836A8 (en) Formulations of ladostigil tartrate
WO2006134021A3 (en) Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof
ZA200806399B (en) Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them
SI1707564T1 (sl) Indanil-piperazinski derivati, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
UA88182C2 (ru) Композиция, которая содержит эпотилон (варианты), и способ ее получения (варианты)
ZA200902413B (en) Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2007071444A3 (en) Esomeprazole arginine
TW200738674A (en) Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine